Linked Life Data

16174656

Source:http://linkedlifedata.com/resource/pubmed/id/16174656

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-12-12
pubmed:abstractText
The aim of the present study was to evaluate the effect of prolonged inhibition of beta-oxidation on glucose and lipid muscle forearm metabolism and cGMP and endothelin-1 forearm release in patients with type 2 diabetes mellitus and ischemic cardiomyopathy. Fifteen patients were randomly allocated in a double-blind cross-over parallel study with trimetazidine (20 mg tid) or placebo lasting 15 days. At the end of each period, all patients underwent euglycemic hyperinsulinemic clamps with forearm indirect calorimetry and endothelial balance of vasodilator and vasoconstricor factors. Compared with placebo, trimetazidine induced 1) an increase in insulin-induced forearm glucose uptake and glucose oxidation accompanied by a reduction in forearm lipid oxidation and citrate release and 2) a decrease of endothelin-1 release paralleled by a significant increase in forearm cGMP release. Forearm glucose oxidation significantly correlated with cGMP release (r=0.37, P<0.04), whereas forearm lipid oxidation positively correlated with endothelin-1 release (r=0.40, P<0.03). In conclusion, for the first time, we demonstrated that insulin-induced forearm glucose oxidation and forearm cGMP release were increased whereas forearm endothelin-1 release was decreased during trimetazidine treatment. Muscle's metabolic and vascular effects of trimetazidine add new interest in the use of trimetazidine in type 2 diabetic patients with cardiovascular disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0193-1849
pubmed:author
pubmed:issnType
Print
pubmed:volume
290
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
E54-E59
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16174656-3-Hydroxybutyric Acid, pubmed-meshheading:16174656-Aged, pubmed-meshheading:16174656-Blood Glucose, pubmed-meshheading:16174656-Citric Acid, pubmed-meshheading:16174656-Cross-Over Studies, pubmed-meshheading:16174656-Cyclic GMP, pubmed-meshheading:16174656-Diabetes Mellitus, Type 2, pubmed-meshheading:16174656-Double-Blind Method, pubmed-meshheading:16174656-Endothelin-1, pubmed-meshheading:16174656-Endothelium, Vascular, pubmed-meshheading:16174656-Fatty Acids, Nonesterified, pubmed-meshheading:16174656-Forearm, pubmed-meshheading:16174656-Glucose, pubmed-meshheading:16174656-Glucose Clamp Technique, pubmed-meshheading:16174656-Humans, pubmed-meshheading:16174656-Insulin, pubmed-meshheading:16174656-Insulin Resistance, pubmed-meshheading:16174656-Lipid Metabolism, pubmed-meshheading:16174656-Male, pubmed-meshheading:16174656-Middle Aged, pubmed-meshheading:16174656-Muscle, Skeletal, pubmed-meshheading:16174656-Myocardial Ischemia, pubmed-meshheading:16174656-Oxidation-Reduction, pubmed-meshheading:16174656-Trimetazidine
pubmed:year
2006
pubmed:articleTitle
Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
pubmed:affiliation
Laboratory L20, Core Lab., Diabetology, Endocrinology and Metabolic Disease Unit, IRCCS H San Raffaele, Via Olgettina 60, 20132 Milan, Italy. monti.lucilla@hsr.it
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't